Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network

Alice Garrett, Alison Callaway, Miranda Durkie, Cankut Cubuk, Mary Alikian, George J Burghel, Rachel Robinson, Louise Izatt, Sabrina Talukdar, Lucy Side, Treena Cranston, Sheila Palmer-Smith, Diana Baralle, Ian R Berry, James Drummond, Andrew J Wallace, Gail Norbury, Diana M Eccles, Sian Ellard, Fiona Laloo, D Gareth Evans, Emma Woodward, Marc Tischkowitz, Helen Hanson, Clare Turnbull

Abstract
Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical sequencing has increased dramatically; and the range of clinical professionals involved in the process has broadened. There is general acceptance that our initial dichotomous paradigms of variants being pathogenic–high risk and benign–no risk are overly simplistic. There is increasing recognition that the clinical interpretation of genomic data requires significant expertise in disease–gene-variant associations specific to each disease area. Inaccurate interpretation can lead to clinical mismanagement, inconsistent information within families and misdirection of resources. It is for this reason that ‘national subspecialist multidisciplinary meetings’ (MDMs) for genomic interpretation have been articulated as key for the new NHS Genomic Medicine Service, of which Cancer Variant Interpretation Group UK (CanVIG-UK) is an early exemplar. CanVIG-UK was established in 2017 and now has >100 UK members, including at least one clinical diagnostic scientist and one clinical cancer geneticist from each of the 25 regional genetics laboratories of the UK and Ireland. Through CanVIG-UK, we have established national consensus around variant interpretation for cancer susceptibility genes via monthly national teleconferenced MDMs and collaborative data sharing using a secure online portal. We describe here the activities of CanVIG-UK, including exemplar outputs and feedback from the membership.

Background
Clinical utility of cancer susceptibility genes (CSGs)
Analysis of germline (constitutional) variants in CSGs constitutes approximately one-quarter of activity in NHS Molecular Diagnostic Laboratories in England. Following identification of a pathogenic variant (PV) in a CSG, incidence of mortality from future cancers may be mitigated via (1) risk-reducing surgery (eg, mastectomy, gastrectomy, salpingo-oophorectomy and colectomy); (2) chemoprevention; (3) intensive screening; and (4) lifestyle modification.2 Family members negative for the familial CSG-PV can be spared anxiety and unnecessary screening. Many CSGs are associated with a pattern of cancer risk that is late-onset, variably penetrant and of autosomal dominant inheritance. PV-positive family members identified via cascade screening are often distributed across disparate genomics services.

Erroneous interpretation of CSG variant pathogenicity can therefore result in (1) discordant management within families, (2) serious clinical consequences for individuals and (3) misdirection at population level of resources for screening and prevention.1–3 Increasingly, CSG-PVs are used as predictive biomarkers to inform cancer therapy. For all these reasons, robust, rapid, accurate variant analysis and interpretation of disease risk are critical to effective delivery of germline cancer genetics and improving outcomes for patients.

Evolving landscape of variant interpretation in germline cancer genetics
In the late 1990s, within a few years of identification of the relevant genes, laboratory analysis of CSGs became available in the UK via family cancer clinics.2 If the cancer phenotype ascribed to the gene matched that found in the proband/family under study, with little additional evidence, a rare variant would often be labelled as pathogenic and thus causative.6 Subsequent large-scale population sequencing studies have revealed the degree of innocuous variation present in the human genome (and indeed in disease-associated genes) and ‘downgrading’ of many erroneously labelled PVs has been required.7 An era of caution followed, with much greater recourse to labelling of variants as ‘variants of uncertain significance’ (VUS/VOUS). However, lack of systems for sharing new evidence has meant that many families have spent years in limbo with their ‘VUS’, even when data had long been available by which classification of their variant could be downgraded or upgraded.

Position statement
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network

Alice Garrett, Alison Callaway, Miranda Durkie, Cankut Cubuk, Mary Alikian, George J Burghel, Rachel Robinson, Louise Izatt, Sabrina Talukdar, Lucy Side, Treena Cranston, Sheila Palmer-Smith, Diana Baralle, Ian R Berry, James Drummond, Andrew J Wallace, Gail Norbury, Diana M Eccles, Sian Ellard, Fiona Laloo, D Gareth Evans, Emma Woodward, Marc Tischkowitz, Helen Hanson, Clare Turnbull

Abstract
Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical sequencing has increased dramatically; and the range of clinical professionals involved in the process has broadened. There is general acceptance that our initial dichotomous paradigms of variants being pathogenic–high risk and benign–no risk are overly simplistic. There is increasing recognition that the clinical interpretation of genomic data requires significant expertise in disease–gene-variant associations specific to each disease area. Inaccurate interpretation can lead to clinical mismanagement, inconsistent information within families and misdirection of resources. It is for this reason that ‘national subspecialist multidisciplinary meetings’ (MDMs) for genomic interpretation have been articulated as key for the new NHS Genomic Medicine Service, of which Cancer Variant Interpretation Group UK (CanVIG-UK) is an early exemplar. CanVIG-UK was established in 2017 and now has >100 UK members, including at least one clinical diagnostic scientist and one clinical cancer geneticist from each of the 25 regional genetics laboratories of the UK and Ireland. Through CanVIG-UK, we have established national consensus around variant interpretation for cancer susceptibility genes via monthly national teleconferenced MDMs and collaborative data sharing using a secure online portal. We describe here the activities of CanVIG-UK, including exemplar outputs and feedback from the membership.

Background
Clinical utility of cancer susceptibility genes (CSGs)
Analysis of germline (constitutional) variants in CSGs constitutes approximately one-quarter of activity in NHS Molecular Diagnostic Laboratories in England. Following identification of a pathogenic variant (PV) in a CSG, incidence of mortality from future cancers may be mitigated via (1) risk-reducing surgery (eg, mastectomy, gastrectomy, salpingo-oophorectomy and colectomy); (2) chemoprevention; (3) intensive screening; and (4) lifestyle modification. Family members negative for the familial CSG-PV can be spared anxiety and unnecessary screening. Many CSGs are associated with a pattern of cancer risk that is late-onset, variably penetrant and of autosomal dominant inheritance. PV-positive family members identified via cascade screening are often distributed across disparate genomics services.

Erroneous interpretation of CSG variant pathogenicity can therefore result in (1) discordant management within families, (2) serious clinical consequences for individuals and (3) misdirection at population level of resources for screening and prevention. Increasingly, CSG-PVs are used as predictive biomarkers to inform cancer therapy. For all these reasons, robust, rapid, accurate variant analysis and interpretation of disease risk are critical to effective delivery of germline cancer genetics and improving outcomes for patients.

Evolving landscape of variant interpretation in germline cancer genetics
In the late 1990s, within a few years of identification of the relevant genes, laboratory analysis of CSGs became available in the UK via family cancer clinics. If the cancer phenotype ascribed to the gene matched that found in the proband/family under study, with little additional evidence, a rare variant would often be labelled as pathogenic and thus causative. Subsequent large-scale population sequencing studies have revealed the degree of innocuous variation present in the human genome (and indeed in disease-associated genes) and ‘downgrading’ of many erroneously labelled PVs has been required. An era of caution followed, with much greater recourse to labelling of variants as ‘variants of uncertain significance’ (VUS/VOUS). However, lack of systems for sharing new evidence has meant that many families have spent years in limbo with their ‘VUS’, even when data had long been available by which classification of their variant could be downgraded or upgraded.

Position statement
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network

Alice Garrett, Alison Callaway, Miranda Durkie, Cankut Cubuk, Mary Alikian, George J Burghel, Rachel Robinson, Louise Izatt, Sabrina Talukdar, Lucy Side, Treena Cranston, Sheila Palmer-Smith, Diana Baralle, Ian R Berry, James Drummond, Andrew J Wallace, Gail Norbury, Diana M Eccles, Sian Ellard, Fiona Laloo, D Gareth Evans, Emma Woodward, Marc Tischkowitz, Helen Hanson, Clare Turnbull

Abstract
Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical sequencing has increased dramatically; and the range of clinical professionals involved in the process has broadened. There is general acceptance that our initial dichotomous paradigms of variants being pathogenic–high risk and benign–no risk are overly simplistic. There is increasing recognition that the clinical interpretation of genomic data requires significant expertise in disease–gene-variant associations specific to each disease area. Inaccurate interpretation can lead to clinical mismanagement, inconsistent information within families and misdirection of resources. It is for this reason that ‘national subspecialist multidisciplinary meetings’ (MDMs) for genomic interpretation have been articulated as key for the new NHS Genomic Medicine Service, of which Cancer Variant Interpretation Group UK (CanVIG-UK) is an early exemplar. CanVIG-UK was established in 2017 and now has >100 UK members, including at least one clinical diagnostic scientist and one clinical cancer geneticist from each of the 25 regional genetics laboratories of the UK and Ireland. Through CanVIG-UK, we have established national consensus around variant interpretation for cancer susceptibility genes via monthly national teleconferenced MDMs and collaborative data sharing using a secure online portal. We describe here the activities of CanVIG-UK, including exemplar outputs and feedback from the membership.

Background
Clinical utility of cancer susceptibility genes (CSGs)
Analysis of germline (constitutional) variants in CSGs constitutes approximately one-quarter of activity in NHS Molecular Diagnostic Laboratories in England. Following identification of a pathogenic variant (PV) in a CSG, incidence of mortality from future cancers may be mitigated via (1) risk-reducing surgery (eg, mastectomy, gastrectomy, salpingo-oophorectomy and colectomy); (2) chemoprevention; (3) intensive screening; and (4) lifestyle modification. Family members negative for the familial CSG-PV can be spared anxiety and unnecessary screening. Many CSGs are associated with a pattern of cancer risk that is late-onset, variably penetrant and of autosomal dominant inheritance. PV-positive family members identified via cascade screening are often distributed across disparate genomics services.

Erroneous interpretation of CSG variant pathogenicity can therefore result in (1) discordant management within families, (2) serious clinical consequences for individuals and (3) misdirection at population level of resources for screening and prevention. Increasingly, CSG-PVs are used as predictive biomarkers to inform cancer therapy. For all these reasons, robust, rapid, accurate variant analysis and interpretation of disease risk are critical to effective delivery of germline cancer genetics and improving outcomes for patients.

Evolving landscape of variant interpretation in germline cancer genetics
In the late 1990s, within a few years of identification of the relevant genes, laboratory analysis of CSGs became available in the UK via family cancer clinics. If the cancer phenotype ascribed to the gene matched that found in the proband/family under study, with little additional evidence, a rare variant would often be labelled as pathogenic and thus causative. Subsequent large-scale population sequencing studies have revealed the degree of innocuous variation present in the human genome (and indeed in disease-associated genes) and ‘downgrading’ of many erroneously labelled PVs has been required. An era of caution followed, with much greater recourse to labelling of variants as ‘variants of uncertain significance’ (VUS/VOUS). However, lack of systems for sharing new evidence has meant that many families have spent years in limbo with their ‘VUS’, even when data had long been available by which classification of their variant could be downgraded or upgraded.
Cancer genetics

Sharing of clinical variant data was somewhat improved with the advent of locus-specific databases (LSDs), such as Breast Cancer Information Core and Leiden Open Variant Databases. However, the curation of clinical and molecular data in LSDs often remains suboptimal, with (1) erroneous nomenclature, (2) duplication of entries and (3) use of differing classification systems resulting in contradictory assignations.

Using Myriad Genetics data from ~70,000 genetic tests for hereditary breast and ovarian cancer, in 2007, Easton and colleagues published a landmark multifactorial analysis through which ‘odds of causality’ were mathematically generated for 1433 variants using clinical, pedigree and allelic data. In 2008, International Agency for Research on Cancer (IARC) collaborators published the first formal five point variant interpretation system for CSGs, which included numeric thresholds for the probability of pathogenicity. Expert cancer susceptibility consortia such as the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) and the International Society for Gastrointestinal Hereditary Tumours (InSIGHT) further evolved these multifactorial variant classification systems to incorporate tumour phenotype and in silico predictions. However, ENIGMA/InSIGHT approaches require statistical genetic–epidemiological analyses of large curated data series and are not reproducible by an individual diagnostic laboratory seeking to classify in a clinically relevant timescale a newly identified variant.

In 2015, the American College of Medical Genetics (ACMG) published a variant interpretation framework enabling the combination by a diagnostic laboratory of disparate evidence sources for a newly identified genomic variant. The ACMG framework has subsequently been further evolved under the auspices of ClinGen, including (1) specification for how it is applied to particular genes and/or diseases (including TP53, CDH1 and PTEN); (2) deeper specification of particular criteria (eg, functional assays); and (3) exposition of the underpinning Bayesian model.

Coordinated national UK approaches in variant interpretation

In 2016, with endorsement from NHS England and Health Education England, it was agreed formally by the UK Association of Clinical Genomic Science (UK-ACGS) to adopt the ACMG variant interpretation framework. The UK-ACGS established national groups for rare disease, germline cancer genetics, cardiac disease and hypercholesterolaemia to develop and disseminate practice in the application of the ACMG variant interpretation framework. In parallel was recognition within the NHS Genomic Medicine Service of the need for national consortia such as the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) and the International Society for Gastrointestinal Hereditary Tumours (InSIGHT) further evolved these multifactorial variant classification systems to incorporate tumour phenotype and in silico predictions.

Objective

The purpose of Cancer Variant Interpretation Group UK (CanVIG-UK) is to advance outcomes for patients by improving the accuracy and consistency of interpretation of variants in Cancer Susceptibility genes across the UK clinical-laboratory community. We have six specific objectives:

1. Creation of a national multidisciplinary professional network and regular forum
2. Training and education.
3. Detailed specification for germline cancer genetics of the UK-ACGS Best Practice Guidelines for Variant Interpretation.
4. Ratification of additional guidance in germline cancer genetics relevant to the UK clinical-laboratory community.
5. Development of an online platform to facilitate information sharing and variant interpretation within the UK clinical-laboratory community.
6. UK contribution to international variant interpretation endeavours.

Training and education

The discussion of cases at the MDM also provides valuable education for the clinical-laboratory community regarding application of the ACMG framework and the vagaries of the evidence sources used (see figure 2). Additionally, through CanVIG-UK, we have supported training of the broader UK genetics and oncology communities in variant interpretation for CSGs.

Detailed specification for germline cancer genetics of the UK-ACGS Best Practice Guidelines for Variant Interpretation

On behalf of the UK-ACGS, the rare disease variant interpretation group has generated and updates annually a highly detailed specification of the ACMG variant interpretation framework. In cancer susceptibility, we typically observe variants relating to late-onset, common phenotypes. De novo and biallelic
A number of challenging issues have emerged, including:

1. Categorisation and management of reduced penetrance variants in high-penetrance genes.
2. Variant interpretation and clinical management for moderate-penetrance genes.
3. Adaptation of variant interpretation and risk for different contexts of ascertainment.
4. Inference of germline findings from tumour-only sequencing.

While germline across genomics, consideration of these issues has become pressing within germline cancer genetics. Benefitting from its regular forum, multidisciplinary membership and alignment with both UK-ACGS and the UK Cancer Genetics Group (UK-CGG), we have used the CanVIG–UK monthly forum to evolve UK national multidisciplinary approaches on such issues (see online supplementary appendix 3).

**Development of an online platform to facilitate information sharing and variant interpretation within the UK clinical-laboratory community**

In germline cancer genetics, enrichment in cases (especially ‘strong families’) is one of the most valuable clinical observations indicating variant pathogenicity. However, to date, we have struggled to quantify such observations on account of (1) failure to aggregate national data from distributed laboratories and (2) lack of a robust denominator.

In a collaborative venture between Public Health England (PHE) and the national network of molecular diagnostic laboratories, data from molecular testing of CSGs have been submitted via a pseudonymisation portal to the secure National Cancer Registration and Analysis Service (NCRAS) data environment of PHE. The national variant totals (numerator and denominator) are then shared by CanVIG–UK with the UK clinical-laboratory community via our online data system CanVar-UK (http://www.canvaruk.org/).

CanVar-UK provides additional annotations for 1008 643 variants from 95 CSGs. It includes variant-level annotations from LSDs (case counts), functional assays, splicing assays and multifactorial analyses for selected genes. Accessible only to registered CanVIG-UK clinical-laboratory users is a community area for sharing non-identifiable variant-level data, such as local classifications, comments/notes, uploaded documents and results from local laboratory assays (eg, RNA analyses of potential splicing variants).

**UK contribution to international variant interpretation endeavours**

CanVIG-UK is an effective conduit between the UK clinical-laboratory germline cancer genetics community and relevant international variant interpretation endeavours in several regards:

► First, there is representation at the international ClinGen SVI group from the leadership of the UK-ACGS rare disease variant interpretation group. The regular cross-talk between leadership of the UK groups enables appraisal of the ClinGen SVI group of emerging analyses and activity within CanVIG-UK and the UK clinical-laboratory cancer genetics community.

► Second, multiple members of CanVIG-UK are members of gene-specific international endeavours such as ENIGMA, InSIGHT and ClinGen expert groups.

► Third, data generated by CanVIG-UK data have contributed to collaborative international consortia analyses, for...
example, provision to ENIGMA of the summary PHE UK laboratory data on BRCA1/BRCA2 variants.

Fourth, CanVIG-UK consensus classifications (and underpinning evidence) are shared via ClinVar. CanVIG-UK is the first UK organisation to submit clinical-laboratory variant classifications to ClinVar.

Sustainability
Maintenance of a national multidisciplinary network, coordination of a regular teleconferenced MDMs and development of a data system is only feasible via sustained support. The activities of CanVIG-UK are currently supported by a Cancer Research UK Catalyst Award (CanGene-CanVar, @CangeneCanvar, C61296/A27223).

CONCLUSION
CanVIG-UK is a multidisciplinary group comprising >100 clinical scientists and senior genetics clinicians working in germline cancer genetics, with representation from across the 25 NHS molecular diagnostic laboratories of the UK and Ireland. Through CanVIG-UK, the UK clinical-laboratory germline cancer genetics community have evolved:

1. An email forum for real-time consultation on problematic variants.
2. A monthly teleconferenced MDM for detailed review of challenging variants and cases.
3. A national programme of using secure submissions of frequency data from PHE.
4. An online data system (CanVar-UK) for sharing variant-level data both publicly and within a secure community region.
5. Detailed, consensus UK guidance for the interpretation of variants in CSGs.
6. Fruitful interactions with international CSG variant interpretation endeavours.

In summary, we propose CanVIG-UK as an exemplar National Subspecialty Multidisciplinary Genomics Network. In this era of rapid emergence of genomic knowledge, such networks are becoming increasingly important to optimise collaborative specialist case review, information sharing and education.

Author affiliations
1Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK
2Wessex Regional Genetics Laboratory, Salisbury Hospital NHS Foundation Trust, Salisbury, UK
3Human Genetics and Genetic Medicine, Faculty of Medicine, University of Southampton, Southampton, UK
4Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK
5William Harvey Research Institute, Queen Mary University of London, London, UK
6Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University NHS Foundation Trust, Manchester, UK
7Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK
8Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK
9Department of Clinical Genetics, Saint George's University Hospitals NHS Foundation Trust, London, UK
10Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK
11Oxford Molecular Genetics Laboratory, Churchill Hospital, Oxford, UK
12Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK
13Faculty of Medicine, University of Southampton, Southampton, UK
14East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
15Regional Genetics Service, Guy's and St Thomas' NHS Foundation Trust, London, UK
16Department of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
17Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK
18Department of Medical Genetics, National Institute for Health, Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
19Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK

Twitter George J Burghel @BurghelG, Ian R Berry @LaughingGenome, Emma Woodward @ER_Woodward and Clare Turnbull @clare_turnbull

Acknowledgements We acknowledge the contribution of Jenny Lord and Andrew Douglas to discussions regarding splicing guidance.

Collaborators CanVIG-UK: Stephen Abbs, Patrick Tarpey, Jonathan Bruty, James Drummond, James Whitworth, Anne Ramsay Bowden, Marc Tischowitz, Eamonn Maher (Cambridge University Hospitals NHS Foundation Trust); Shirley Hegarty, Sean Hegarty, Rosalind Martin, Peter Logan, Claire Byrne (Belfast Health and Social...
Cancer genetics highlight the importance of clinical confirmation testing for appropriate patient care.


Cancer genetics


28 Cox JH. Available: https://www.openpseudonymiser.org/About.aspx